359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
The Readout Loud
00:00
Navigating Obesity Drugs and Cell Therapies
This chapter examines the challenges faced by Amgen with its obesity drug, focusing on side effects and trial discontinuation rates. It highlights innovative therapies for type 1 diabetes and explores the evolving landscape of cell and gene therapies, including CAR-T advancements. The discussion balances skepticism about drug efficacy with hope for breakthroughs in treating chronic diseases.
Transcript
Play full episode
